Ellington Management Group’s Akebia Therapeutics AKBA Stock Holding History

Ellington Management Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-21,800	Closed	-$121K	–	553
2018 Q4	$121K	Buy	+21,800	New	+$171K	0.04%	344
2018 Q2	–	Sell	-11,700	Closed	-$112K	–	486
2018 Q1	$112K	Buy	+11,700	New	+$164K	0.01%	777
2017 Q4	–	Sell	-12,100	Closed	-$238K	–	575
2017 Q3	$238K	Buy	+12,100	New	+$186K	0.04%	470
2017 Q1	–	Sell	-11,500	Closed	-$120K	–	667
2016 Q4	$120K	Sell	11,500 -5,700	-33%	-$49.1K	0.02%	486
2016 Q3	$156K	Buy	+17,200	New	+$146K	0.04%	576
2016 Q1	–	Sell	-44,906	Closed	-$580K	–	486
2015 Q4	$580K	Buy	44,906 +16,509	+58%	+$168K	0.2%	84
2015 Q3	$274K	Buy	+28,397	New	+$261K	0.08%	449

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Ellington Management Group's AKBA Position: Q1 2019 in Review

Ellington Management Group sold out of Akebia Therapeutics (AKBA) in Q1 2019, closing a stake of 21,800 shares — an estimated $121K sold.

Ellington Management Group first reported a position in AKBA in Q3 2015 and held it in 7 quarters. The position peaked at $580K in Q4 2015. 169 funds tracked by Wall St. Rank hold AKBA as of Q1 2019.

Ellington Management Group reported no remaining Akebia Therapeutics position as of Q1 2019 after selling out during the quarter.
Ellington Management Group sold 21,800 Akebia Therapeutics shares in Q1 2019, an estimated $121K.
Ellington Management Group first reported a position in Akebia Therapeutics in Q3 2015 and held it in 7 quarters.
Ellington Management Group's Akebia Therapeutics position peaked at $580K in Q4 2015.
169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2019.

Based on Ellington Management Group's 13F filing for Q1 2019, filed 15 May 2019.